Sheraz - Iran
Background. Data concerning the interrelationship of antiphospholipid antibodies (aPL) and myocardial infarction (MI) in patients with acute myocardial infarction and no evidence of overt autoimmune disease is conflicting. The present study is to determine the presence of aPL antibodies in a group of patients with acute myocardial infarction (AMI), under the age of 45 year, and with no evidence of major risk factors for coronary artery disease.
Methods: 42 patients with acute myocardial infarction, under the age of 45 years, who were admitted in cardiac care unit and 40 healthy subjects, as controls, were included in this study. Sera were drawn both from the patients and control subjects for VDRL test and antibodies against phospholipids .
Results: Antiphospholipid antibodies and false-positive VDRL were documented in 10 patients out of 42 studied subjects (23.8%). None of the control subjects had positive aPL antibodies or false-positive VDRL (P value 0.001). This shows young individuals (under 45 years) with AMI have a relative risk (RR) of 2.25 for aPL antibodies compared with the normal population. .
Conclusion: There is a strong relationship between aPL antibodies and AMI in individuals under the age of 45 years. The presence of a high aPL antibody titer is an independent risk factor for AML Therefore in young patients (especially under the age of 45 years) with AMI, screening tests for the presence of aPL antibodies is recommended (Iranian Heart Journal 2002, 2003; 3(4&4(1): 61-64).